Test the Outdoor Usage for Sunscreen Products in Female Adults
NCT02779270 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 105
Last updated 2018-12-12
Summary
To assess the safety of a sunscreen product when used outdoor.
Conditions
- Sunscreening Agents
Interventions
- DRUG
-
BAY987518
Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids. Formulation: V27-104
- DRUG
-
Sunscreen Lotion (U77-030 Control)
Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bayer Study Director · Bayer
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-09-26
- Primary Completion
- 2015-09-27
- Completion
- 2015-09-27
Countries
- United States
Study Locations
More Related Trials
-
Human Phototoxicity Test
NCT02751541 ·Status: COMPLETED ·Phase: NA
-
Pharmacokinetic (PK) Evaluation of Bemotrizinol (6%) in a Sunscreen Maximum Usage Trial
NCT05277376 ·Status: COMPLETED ·Phase: PHASE3
-
Kinetic Time Courses of Bisphenol-S in Volunteers
NCT03340168 ·Status: UNKNOWN ·Phase: NA
-
Phototoxicity of Frequently Prescribed Medicines
NCT06710600 ·Status: COMPLETED ·Phase: NA
-
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function
NCT05283915 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers
NCT05830799 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of TAK-279 in Adults With or Without Liver Damage
NCT05976321 ·Status: COMPLETED ·Phase: PHASE1
-
Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)
NCT05093972 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment
NCT00359177 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Study of Seresis® in the Skin in Healthy Young Female Volunteers
NCT02191852 ·Status: COMPLETED ·Phase: PHASE1
-
Study of NST-6179 in Healthy Subjects
NCT05181085 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function
NCT01367522 ·Status: COMPLETED ·Phase: PHASE1
-
Validation of Drug Assays in Various Biological Matrices
NCT02283112 ·Status: RECRUITING
-
Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers
NCT01336387 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of CSL112 in Healthy Adults and in Adults With Moderate Renal Impairment
NCT02427035 ·Status: COMPLETED ·Phase: PHASE1
-
A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT
NCT04193436 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers
NCT02668367 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of BPDO-1603 or BPDO-16031 and BPDO-16033 Administration in Healthy Adults
NCT05804279 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects
NCT01487239 ·Status: COMPLETED ·Phase: PHASE1
-
PK Study of T-817 in Subjects With Hepatic Impairment
NCT02693197 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers
NCT01711762 ·Status: COMPLETED ·Phase: PHASE1
-
A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
NCT04332432 ·Status: COMPLETED ·Phase: PHASE1
-
Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States
NCT01722669 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants
NCT02982707 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions
NCT03603106 ·Status: COMPLETED ·Phase: PHASE1/PHASE2